(0.34%) 5 117.09 points
(0.33%) 38 367 points
(0.40%) 15 991 points
(-0.98%) $83.03
(5.51%) $2.03
(0.33%) $2 354.90
(0.46%) $27.66
(4.06%) $959.55
(-0.26%) $0.932
(-0.42%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
3 days till quarter result
(tns 2024-05-02)
Expected move: +/- 11.39%
Live Chart Being Loaded With Signals
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...
Stats | |
---|---|
本日の出来高 | 1.46M |
平均出来高 | 798 146 |
時価総額 | 65.08M |
EPS | $0 ( 2024-03-07 ) |
次の収益日 | ( $0 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.686 |
ATR14 | $0.0570 (5.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
INSIDER POWER |
---|
-73.51 |
Last 94 transactions |
Buy: 4 462 585 | Sell: 5 534 482 |
ボリューム 相関
Surface Oncology Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Surface Oncology Inc 相関 - 通貨/商品
Surface Oncology Inc 財務諸表
Annual | 2022 |
収益: | $30.00M |
総利益: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2022 |
収益: | $30.00M |
総利益: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2021 |
収益: | $2.69M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.735 |
FY | 2020 |
収益: | $126.16M |
総利益: | $0.00 (0.00 %) |
EPS: | $1.670 |
Financial Reports:
No articles found.
Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。